Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

The investigational uses of Libtayo, fianlimab ... and odronextamab have received conditional approval in the European Union for certain hematologic conditions. Trading at a P/E ratio of 14.2 ...

The investigational uses of Libtayo, fianlimab, REGN7075 ... while linvoseltamab and odronextamab have received conditional approval in the European Union for certain hematologic conditions. Trading ...

Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous squamous cell carcinoma and data on linvoseltamab for relapsed or refractory multiple myeloma. Other research ...

Europe's vulnerability doesn't end with card payments. Increasingly, consumers are paying with smartphones via apps, where American tech firms like Apple Pay , Google Pay , and PayPal lead the market.

30 Under 30 Europe Entertainment 2025: Ella Purnell, Alan Walker, Lola Young And The Rising Stars On Screen And On Stage 30 Under 30 Europe Manufacturing & Industry 2025: Europe’s Top Industrial ...

R.E.M. disbanded back in 2011. But the seminal indie-rock group is back with new five-track EP “Radio Free Europe 2025,”containing previously unreleased tracks and a new remix of the song.

Clinical Trial Supply Agreement Announced with Regeneron for Libtayo (cemiplimab): In February, Immuneering announced a clinical trial supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 ...